Flavonoid · Fact sheet

Quercetin

Quercetin is a plant flavonoid with small human studies of blood pressure and biomarkers. Results are mixed, and studies combining it with dasatinib cannot establish the effects of quercetin alone.

Not FDA approvedEarly human evidence

What is Quercetin?

Quercetin is present in many plant foods and is also studied as a concentrated supplement. It is distinct from the experimental dasatinib–quercetin drug combination.

Benefits & claims

Inflammation, immune support, allergies, cardiovascular health, and senescent-cell clearance attract interest. These are separate claims with different evidence requirements.

What the evidence supports

  • One 93-person study found a modest reduction in systolic blood pressure.
  • Mixed overall and subgroup findings do not establish prevention of cardiovascular events or a longevity benefit.
Research areas
  • Blood pressure
  • Oxidative-stress markers
  • Senescence-related research

Dosage & frequency

Human study context

Quercetin supplement studies do not establish a senolytic or longevity prescription. Quercetin alone is different from the experimental dasatinib–quercetin combination.

Randomized cardiovascular-risk crossover study

Overweight adults with a high-cardiovascular-risk phenotype

Amount
150 mg/day
Frequency
Daily during six-week study periods
Route studied or labeled
Oral

Blood-pressure and biomarker research; not a senolytic prescription.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Food intake, supplement formulations, and combination trials represent different exposures.

Interactions & precautions

  • A cardiovascular-risk supplement trial does not establish high-dose interaction safety, particularly for the separate dasatinib–quercetin combination.

What is still unresolved

  • A clinically effective regimen, long-term benefit, and interaction profile at high exposure remain uncertain.

Side effects & risks

  • Short studies in selected participants do not establish long-term safety or uncommon side-effect rates.
  • Findings from a combination with a prescription cancer medicine cannot be used as a safety assessment of either ingredient alone.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Short crossover studies report small blood-pressure changes in selected groups. A 70-person trial found no overall effect on 24-hour blood pressure, although a hypertension subgroup improved.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Clearer thinking, with ongoing sleep problems

An author described less brain fog, fatigue and distress after adding quercetin with bromelain. Insomnia and itchy eyes and throat persisted.

Reported use in this account

Product
Quercetin with bromelain capsules
Amount
800 mg in two capsules, as reported
Frequency
Daily, in the morning
Route
Oral capsules
Duration
Three weeks at the time of the post

Other exposures described: Bromelain; Pepcid (famotidine); Zyrtec (cetirizine); NAC; Other vitamins

The author had no confirmed MCAS diagnosis and also used antihistamines, NAC and vitamins. Improvement cannot be assigned to quercetin alone.

Read the original account

Approval status

Quercetin has no FDA-approved drug indication for the wellness uses discussed here. Supplement availability is not premarket FDA approval of effectiveness or safety.

Supplement research is not FDA drug approval

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Clinical outcomes beyond small biomarker changes
  • Long-term supplement safety and interactions
  • Effects of quercetin alone on senescent cells in humans

Summary

Mixed overall and subgroup findings do not establish prevention of cardiovascular events or a longevity benefit.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedQuercetin crossover study in adults with metabolic risk

    93 participants; small systolic blood-pressure changes over six-week periods.

  2. pubmedQuercetin and ambulatory blood pressure

    No overall 24-hour blood-pressure effect; a hypertensive subgroup differed.

  3. fdaFDA: what approval means for supplements

    Dietary supplements are not approved by FDA for safety and effectiveness before marketing.

How we assess sources · Suggest a correction